Last reviewed · How we verify
ATS907
ATS907 is a small molecule that targets the S1P1 receptor.
ATS907 is a small molecule that targets the S1P1 receptor. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | ATS907 |
|---|---|
| Sponsor | Altheos, Inc. |
| Drug class | S1P1 receptor antagonist |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
ATS907 acts as a selective S1P1 receptor antagonist, which has been shown to have anti-inflammatory effects. This mechanism of action is being explored for the treatment of various autoimmune diseases.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (PHASE1, PHASE2)
- ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATS907 CI brief — competitive landscape report
- ATS907 updates RSS · CI watch RSS
- Altheos, Inc. portfolio CI